Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

Fintel reports that on November 5, 2024, William Blair initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Camp4 Therapeutics (CAMP) stock gains after J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...

CAMP4 Therapeutics Corporation (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the ...

Dutch biotech investor Forbion raised €2.1 billion for two new biotech funds. Terray Therapeutics raised a $120 million Series B round. Camp4 Therapeutics raised $75 million in an initial public ...

Camp4 Therapeutics Corp (NASDAQ:CAMP) saw multiple insiders make substantial purchases: • Polaris (NYSE:PII) Partners X, L.P., a significant stakeholder in Camp4 Therapeutics Corp, acquired 909,090 ...

Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), reported a sale of 1,089 common shares valued at approximately $50,398, according to... In a recent transaction ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...